Our HPV self-collection solution* and pTau217 assay** were recognized in the Medical Care category, among 200 overall Best Invention recipients. These medical innovations aim to make cervical cancer screening and Alzheimer's diagnosis more accessible and effective.
*HPV self-collection is not yet available in the U.S. Anticipated commercial availability begins in November 2024.
**The pTau217 assay is available for research use only, not for use in diagnostic procedures.
A similar version of the assay is under development and received FDA Breakthrough Device Designation.
The new VENTANA CLDN18 (43-14A) RxDx Assay helps fulfill an unmet medical need by enabling clinicians to identify patients with gastric or gastroesophageal junction (GEJ) cancer.
The VENTANA DP 200 slide scanner is now cleared to aid in clinical diagnosis, enabling pathologists to diagnose patients using digital images.
Now, HCPs will be able to detect and differentiate these respiratory viruses within a single patient visit, enabling improved public health outcomes.
Learn more about our portfolio of lab instruments, systems, assays and more
More than 800,000 documents available on demand — always up-to-date with 24/7 access
